For the fourth quarter of fiscal 2011, revenues were $5,218,000 compared to $3,814,000 for the fourth quarter of fiscal 2010. Gross profit was $1,798,000, with gross profit margin of 34%, compared to gross profit of $1,387,000 and gross profit margin of 36% for 4Q ’10. Net income was $795,000 or $.14 per diluted share, compared to net loss of $226,000 or $(0.04) per diluted share last fiscal year.

Fiscal Year 2011

For the fiscal year ended March 31, 2011, revenues were $16,827,000 compared to revenues of $15,742,000 for the year ended March 31, 2010. Gross profit was $6,341,000, with gross profit margin of 38%, compared to gross profit of $6,633,000 and gross profit margin of 42% in fiscal 2010. Net income was $1,730,000 or $.32 per diluted share, compared to $1,391,000, or $0.26 per diluted share fiscal year 2010.

For fiscal 2011, Spirulina sales accounted for 50% of total revenues and natural Astaxanthin sales for 50%. International sales were 42% of total sales.

More info

In 2002, FEBICO continued studies on the types of viruses the Apogen is capable of suppressing. The research shows that the Apogen microalgae protein is capable of suppressing 6 types of enterovirus, Influenza virus A / B type, and 9 types of herpes simplex virus. In 2006 FEBICO also began researches on respiratory rotavirus. According to National Taiwan University’s empirical studies, Apogen once again proves that it is effective in suppressing respiratory rotavirus. Ensuring that the Apogen microalgae protein is a multifunctional type of material that is capable of suppressing different types of viruses.

Apogen microalgae protein is extracted from natural spirulina. It is water soluble, safe to use and is currently being produced into different types of dosages, including tablets or powder form. It can protect oral mucosa cells, form protective protection films and prevent virus attacks, which makes it a natural immune remedy against viruses.

More info

Sanat is a broad based producer of Herbal Extract, natural health care products and herbal Pharmaceuticals.  Applying the rigors of pharmaceutical quality to the natural product sector insures a level of excellence expected by consumers worldwide. Fuji is similarly based in pharmaceuticals along with the development and production of high performing excipients as well as unique nutritional ingredients. Both companies are involved in the cultivation of microalgae for natural human health benefit.  Fuji is a world leader in the production of natural astaxanthin from the single cell microalgae, Haematococcus pluvialis and Sanat is a major producer of Organic spirulina.

Charles DePrince, president of Fuji Health said, “I see a synergy between the technologies of both companies that when combined has the potential to expand the scope of our product offerings in the market.”

“We envision our collaboration and cooperation within the sphere of Microalgae and related product marketing as an augmented step in more effectively reaching the customer base in North America,” said Amit Sharma, General Manager – International Business of Sanat Products Limited.

• Immune System Enhancement
• Anti-Viral Activity
• Cardiovascular Health
• Cancer Prevention

The wealth of research for Spirulina in these four vital areas is reaching critical mass, and the Cyanotech personnel who authored this paper make a strong case for the use of Spirulina to benefit people concerned with these key health issues. This article, “Potential Health Benefits of Spirulina Microalgae” (Capelli and Cysewski, 2010), which appeared in the last issue of NutraFoods is available as a PDF and at the company’s website www.cyanotech.com

BNPD, formerly Bionic Products, Inc., is currently undergoing a formal name change to Biocen Natural Products Development, Inc. All corporate information is currently being updated and the official name change will be announced when approval has been received from the regulatory authorities.

The details of the contract between BNPD and BEHL are as followed, states Ms. Berry, “The first part of the contract is a $600,000 licensing and royalty agreement for representation of BEHL and BEHL clients for specific algaes produced. BNPD has agreed to pay BioCentric Energy in 8 equal installments commencing on September 14, 2010. As the market demand fluctuates for the end products, the licensing fee may be amended annually.”

In addition to the licensing agreement, both companies have agreed upon and executed a sole and exclusive sales and marketing contract in which BNPD will purchase from BioCentric Energy and its clients 3 specific algae strains to be used in BNPD’s health and nutracuetical products.

The first algae strain, Haemaotoccocus, has a current market value of $341 per kilogram. Conservatively, BEHL will produce 15,600 pounds of Haemaotoccocus over the next 12 months for BNPD. The next strain grown by BEHL and/or clients sold to BNPD will be the very popular, robust and fast growing Chlorella.

The current market value for Chlorella is $44 per kilogram. BioCentric Energy will deliver to BNPD, 12,000 pounds of Chlorella over the next 12 months. Finally, the highly popular algae known for its antioxidant and anticancer properties, Spirulina, will also be produced and delivered to BNPD. The current market value for Spirulina is $20 per kilogram. BioCentric Energy plans to produce and deliver approximately 22,500 pounds of Spirulina over the next 12 months.

More info

Under a $1.4 million project funded by the European Union and run by FAO the women are gathering and processing increasing quantities of a remarkable produce known locally as Dihé, a variety of the blue-green algae called Spirulina.

Dihé is a rich source of protein, iron and betacarotene and can enhance the nutritional value of diets that are poor in these nutrients.

More info

Source: Cyanotech